NCT02542514已完成2 期
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma
The Lymphoma Academic Research Organisation10 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2015年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 52
- 试验地点
- 10
- 主要终点
- disease control rate (CR + CRu + PR +SD)
研究概览
简要总结
The study is an open label, prospective, multicenter, phase II study which aims to define ibrutinib efficacy in patients with relapsed or refractory primary central nervous lymphoma (PCNSL) or intraocular lymphoma (IOL) as measured by the disease control (DC) rate (complete response (CR) + uncertain complete response (Ru) + partial response (PR) stabilized disease (SD)) after 2 cycles of treatment according to International study group for PCNSL (IPCG) criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of PCNSL or cytologically proven diagnosis of IOL or lymphomatous meningitis of B-cell type. In case of CNS lymphoma relapse or refractory PCNSL, cerebral biopsies are not required if imaging reveals typical images of PCNSL. In case of isolated IOL relapse, vitrectomy is not required if i) vitrectomy was part of the initial diagnosis workout, and ii) ocular examination and dosage of IL-10 in the anterior chamber of the eye performed at relapse or progression are highly in favour of IOL relapse (> 50 pg/ml in aqueous humor or 400 pg/ml in vitreous).
- •Aged 18 years and older.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or
- •Life expectancy ≥ 3 months.
- •No more than 4 lines of anti-cancer treatment received.
- •Patients must have recovered within 28 days to a grade ≤ 1 from all toxicities related to prior treatments.
- •Adequate Laboratory Parameters within 14 days:
- •Measurable PCNSL as diagnosed on MRI
- •Highly effective method of birth control during and after the study consistent. Men must agree to not donate sperm during and after the study. These restrictions apply for 1 year after the last dose of study drug.
- •Women of childbearing potential must have a negative serum beta-hCG or urine pregnancy test at Screening.
- •Sign of an informed consent document.The informed consent document can be signed by a person of confidence in case neurologic disorders related to the disease prevent the patient to sign himself.
排除标准
- •Contraindication to any excipients of the drug.
- •T-cell lymphoma.
- •Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast), prior history of systemic lymphoma, unless the patient has been free of the disease for ≥ 3 years.
- •Prior history of organ transplantation or other cause of severe immunodeficiency.
- •Major surgery, within 4 weeks prior to the first dose of study drug.
- •History of stroke or intracranial hemorrhage within 6 months prior to randomization. Patients with post-biopsies hemorrhagic sequela defined as a small hyperdense lesion < 3 mm on T2* sequence won't be excluded.
- •Requires anticoagulation with warfarin or equivalent vitamin K antagonists or ongoing warfarin medication or other equivalent vitamin K antagonists.
- •Any anti-platelet aggregant medication except acetyl salicylic acid ≤ 75 mg/day.
- •Requires treatment with strong CYP3A4 inhibitors.
- •Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or Class 4 cardiac disease as defined by the New York Heart Association Functional Classification.
- •Vaccinated with live, attenuated vaccines within 4 weeks prior to the first dose of study drug.
- •Known history of HIV or active Hepatitis C Virus (HCV; RNA polymerase chain reaction [PCR]-positive) or active Hepatitis B Virus (HBs Ag positive or DNA PCR-positive) infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics.
- •Any life-threatening illness, medical condition, or organ system dysfunction which could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
- •Inability to swallow capsules.
- •Pregnancy or lactation.
- •Use of anti-cancer drug therapy within 21 days prior to the first dose of study drug.
- •Previous treatment by BTK inhibitors and PI3K inhibitors.
- •Known bleeding diathesis.
- •Inclusion in another experimental anti-cancer drug therapy*.
- •Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
- •Patient under measure of legal protection.
- •No social security affiliation.
研究组 & 干预措施
Ibrutinib
Experimental
ibrutinib in monotherapy 28 days/cycles
干预措施: Ibrutinib (Drug)
结局指标
主要结局
disease control rate (CR + CRu + PR +SD)
时间窗: 2 months
Disease control (DC) rate (CR + CRu + PR + SD) after 2 cycles of treatment according to IPCG criteria.
次要结局
- time to progression(12 months)
- progression-free survival (PFS)(12 months)
- complete response (CR) rate(4, 6, 9 and 12 months)
- overall survival (OS)(4, 6, 9 and 12 months)
- disease control(4, 6, 9 and 12 months)
- overall response (OR)(4, 6, 9 and 12 months)
- Number of AE(12 months)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host DiseaseGraft Versus Host DiseaseNCT02195869Pharmacyclics LLC.45
已完成
2 期
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaNon-Hodgkin's LymphomaB-cell LymphomaFollicular LymphomaNCT01980654Pharmacyclics LLC.80
终止
2 期
Study of Ibrutinib in Subjects With Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)NCT02351037Pharmacyclics LLC.36
已完成
2 期
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT02902965Pharmacyclics Switzerland GmbH74
招募中
2 期
The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaRefractory/Relapsed Autoimmune Hemolytic AnemiaNCT04398459Institute of Hematology & Blood Diseases Hospital, China18